|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/13/12 Biolase, Inc 10-K 12/31/11 35:3.9M Donnelley … Solutions/FA |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 1.05M
2: EX-10.32 Material Contract HTML 31K
3: EX-21.1 Subsidiaries List HTML 10K
4: EX-23.1 Consent of Experts or Counsel HTML 12K
5: EX-31.1 Certification -- §302 - SOA'02 HTML 17K
6: EX-31.2 Certification -- §302 - SOA'02 HTML 17K
7: EX-32.1 Certification -- §906 - SOA'02 HTML 14K
8: EX-32.2 Certification -- §906 - SOA'02 HTML 14K
23: R1 Document and Entity Information HTML 42K
18: R2 Consolidated Balance Sheets HTML 140K
21: R3 Consolidated Balance Sheets (Parenthetical) HTML 43K
25: R4 Consolidated Statements of Operations HTML 97K
33: R5 Consolidated Statements of Stockholders' Equity HTML 89K
(Deficit) And Comprehensive Loss
19: R6 Consolidated Statements of Cash Flows HTML 161K
20: R7 Basis of Presentation HTML 43K
17: R8 Summary of Significant Accounting Policies HTML 88K
15: R9 Supplementary Balance Sheet Information HTML 66K
34: R10 Intangible Assets and Goodwill HTML 45K
27: R11 Bank Line of Credit and Debt HTML 22K
26: R12 Income Taxes HTML 84K
29: R13 Commitments and Contingencies HTML 37K
30: R14 Stockholders' Equity (Deficit) HTML 97K
28: R15 Segment Information HTML 30K
31: R16 Concentrations HTML 17K
22: R17 Subsequent Events HTML 18K
24: R18 Consolidated Valuation and Qualifying Accounts and HTML 35K
Reserves
35: XML IDEA XML File -- Filing Summary XML 40K
16: EXCEL IDEA Workbook of Financial Reports (.xls) XLS 445K
9: EX-101.INS XBRL Instance -- blti-20111231 XML 606K
11: EX-101.CAL XBRL Calculations -- blti-20111231_cal XML 114K
12: EX-101.DEF XBRL Definitions -- blti-20111231_def XML 47K
13: EX-101.LAB XBRL Labels -- blti-20111231_lab XML 406K
14: EX-101.PRE XBRL Presentations -- blti-20111231_pre XML 240K
10: EX-101.SCH XBRL Schema -- blti-20111231 XSD 46K
32: ZIP XBRL Zipped Folder -- 0001193125-12-112386-xbrl Zip 70K
| EX-31.1 |
Exhibit 31.1
CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Federico Pignatelli, certify that:
1. I have reviewed this Annual Report on Form 10-K of BIOLASE Technology, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations, and cash flows of the Registrant as of, and for, the periods presented in this report;
4. The Registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:
a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this annual report is being prepared;
b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c) evaluated the effectiveness of the Registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d) disclosed in this report any change in the Registrant’s internal control over financial reporting that occurred during the Registrant’s fourth fiscal quarter ended December 31, 2011 that has materially affected, or is reasonably likely to materially affect, the Registrant’s internal control over financial reporting;
5. The Registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant’s auditors and the audit committee of Registrant’s board of directors (or persons performing the equivalent functions):
a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant’s ability to record, process, summarize, and report financial information; and
b) any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant’s internal control over financial reporting.
| Date: March 13, 2012 | ||||||
| By: | /s/ FEDERICO PIGNATELLI | |||||
| Federico Pignatelli | ||||||
| Chief Executive Officer (Principal Executive Officer) | ||||||
| This ‘10-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 3/13/12 | 4 | ||
| For Period end: | 12/31/11 | 10-K/A | ||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 12/11/12 SEC UPLOAD¶ 9/28/17 1:36K Biolase, Inc. 11/27/12 SEC UPLOAD¶ 9/28/17 1:155K Biolase, Inc. |